Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hoppe

Showing results (181-190 of 287) with videos related to

Pageof 29
Sort By:
Plos Genetics|January 14, 2014
C/EBPα is required for long-term self-renewal and lineage priming of hematopoietic stem cells and for the maintenance of epigenetic configurations in multipotent progenitorsMarie S Hasemann, Felicia K B Lauridsen, Johannes Waage, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2016
Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused UltrasoundAdam L Holtzman, Bradford S Hoppe, Haley P Letter, et al.
Haematologica|December 22, 2022
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PETKaran L Chohan, Jason R Young, Scott Lester, et al.
Acta Oncologica (Stockholm, Sweden)|March 13, 2013
Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppressionWhoon Jong Kil, Romaine C Nichols, Bradford S Hoppe, et al.
American Journal of Clinical Oncology|May 5, 2018
Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker PlacementWilliam M Mendenhall, Gail Sarto, Curtis M Bryant, et al.
Blood Advances|May 26, 2022
A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcomeKaran L Chohan, Jason R Young, Scott Lester, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology GroupRahul R Parikh, Kara M Kelly, David C Hodgson, et al.
Cell Stem Cell|November 30, 2021
Genome-wide screening in human kidney organoids identifies developmental and disease-related aspects of nephrogenesisRosemarie Ungricht, Laure Guibbal, Marie-Christine Lasbennes, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida Proton Therapy InstituteRovel J Colaco, Bradford S Hoppe, Stella Flampouri, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2022
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 TrialBradford S Hoppe, Romaine C Nichols, Stella Flampouri, et al.
Pageof 29

Showing results (181-190 of 287) with videos related to

Sort By:
Pageof 29
Plos Genetics|January 14, 2014
C/EBPα is required for long-term self-renewal and lineage priming of hematopoietic stem cells and for the maintenance of epigenetic configurations in multipotent progenitorsMarie S Hasemann, Felicia K B Lauridsen, Johannes Waage, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2016
Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused UltrasoundAdam L Holtzman, Bradford S Hoppe, Haley P Letter, et al.
Haematologica|December 22, 2022
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PETKaran L Chohan, Jason R Young, Scott Lester, et al.
Acta Oncologica (Stockholm, Sweden)|March 13, 2013
Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppressionWhoon Jong Kil, Romaine C Nichols, Bradford S Hoppe, et al.
American Journal of Clinical Oncology|May 5, 2018
Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker PlacementWilliam M Mendenhall, Gail Sarto, Curtis M Bryant, et al.
Blood Advances|May 26, 2022
A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcomeKaran L Chohan, Jason R Young, Scott Lester, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology GroupRahul R Parikh, Kara M Kelly, David C Hodgson, et al.
Cell Stem Cell|November 30, 2021
Genome-wide screening in human kidney organoids identifies developmental and disease-related aspects of nephrogenesisRosemarie Ungricht, Laure Guibbal, Marie-Christine Lasbennes, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida Proton Therapy InstituteRovel J Colaco, Bradford S Hoppe, Stella Flampouri, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2022
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 TrialBradford S Hoppe, Romaine C Nichols, Stella Flampouri, et al.
Pageof 29